vs

Side-by-side financial comparison of AWARE INC (AWRE) and Roivant Sciences Ltd. (ROIV). Click either name above to swap in a different company.

AWARE INC is the larger business by last-quarter revenue ($3.4M vs $2.0M, roughly 1.7× Roivant Sciences Ltd.). On growth, AWARE INC posted the faster year-over-year revenue change (-6.2% vs -77.8%). Over the past eight quarters, AWARE INC's revenue compounded faster (-11.5% CAGR vs -73.7%).

AWARE Inc. is a technology firm specializing in biometric software and identity verification solutions. It develops fingerprint, facial, and iris recognition tools, serving government agencies, financial institutions, and enterprise clients primarily across North America and global regulated markets.

Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.

AWRE vs ROIV — Head-to-Head

Bigger by revenue
AWRE
AWRE
1.7× larger
AWRE
$3.4M
$2.0M
ROIV
Growing faster (revenue YoY)
AWRE
AWRE
+71.7% gap
AWRE
-6.2%
-77.8%
ROIV
Faster 2-yr revenue CAGR
AWRE
AWRE
Annualised
AWRE
-11.5%
-73.7%
ROIV

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
AWRE
AWRE
ROIV
ROIV
Revenue
$3.4M
$2.0M
Net Profit
$-265.9M
Gross Margin
90.1%
Operating Margin
-107.8%
-16966.1%
Net Margin
-13301.2%
Revenue YoY
-6.2%
-77.8%
Net Profit YoY
-257.0%
EPS (diluted)
$-0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AWRE
AWRE
ROIV
ROIV
Q1 26
$3.4M
Q4 25
$4.7M
$2.0M
Q3 25
$5.1M
$1.6M
Q2 25
$3.9M
$2.2M
Q1 25
$3.6M
$-39.6M
Q4 24
$4.8M
$9.0M
Q3 24
$3.8M
$4.5M
Q2 24
$4.3M
$8.0M
Net Profit
AWRE
AWRE
ROIV
ROIV
Q1 26
Q4 25
$-1.5M
$-265.9M
Q3 25
$-1.1M
$-113.5M
Q2 25
$-1.8M
$-223.4M
Q1 25
$-1.6M
$-206.5M
Q4 24
$-1.2M
$169.4M
Q3 24
$-1.2M
$-230.2M
Q2 24
$-1.1M
$95.3M
Gross Margin
AWRE
AWRE
ROIV
ROIV
Q1 26
90.1%
Q4 25
94.7%
Q3 25
90.4%
Q2 25
91.3%
Q1 25
93.2%
Q4 24
99.6%
Q3 24
93.0%
Q2 24
93.8%
Operating Margin
AWRE
AWRE
ROIV
ROIV
Q1 26
-107.8%
Q4 25
-31.1%
-16966.1%
Q3 25
-25.2%
-19492.9%
Q2 25
-50.3%
-13130.0%
Q1 25
-51.3%
674.8%
Q4 24
-30.7%
-3042.6%
Q3 24
-38.1%
-7636.0%
Q2 24
-31.0%
-1279.5%
Net Margin
AWRE
AWRE
ROIV
ROIV
Q1 26
Q4 25
-31.2%
-13301.2%
Q3 25
-20.5%
-7225.9%
Q2 25
-45.4%
-10292.9%
Q1 25
-44.3%
521.8%
Q4 24
-24.8%
1878.3%
Q3 24
-30.3%
-5143.8%
Q2 24
-25.2%
1192.7%
EPS (diluted)
AWRE
AWRE
ROIV
ROIV
Q1 26
Q4 25
$-0.07
$-0.38
Q3 25
$-0.05
$-0.17
Q2 25
$-0.08
$-0.33
Q1 25
$-0.08
$-0.28
Q4 24
$-0.05
$0.23
Q3 24
$-0.06
$-0.31
Q2 24
$-0.05
$0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AWRE
AWRE
ROIV
ROIV
Cash + ST InvestmentsLiquidity on hand
$4.6M
$4.5B
Total DebtLower is stronger
Stockholders' EquityBook value
$4.3B
Total Assets
$33.2M
$5.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AWRE
AWRE
ROIV
ROIV
Q1 26
$4.6M
Q4 25
$7.3M
$4.5B
Q3 25
$6.3M
$4.4B
Q2 25
$7.3M
$4.5B
Q1 25
$8.5M
$4.9B
Q4 24
$13.0M
$5.1B
Q3 24
$11.2M
$5.4B
Q2 24
$11.5M
$5.7B
Total Debt
AWRE
AWRE
ROIV
ROIV
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$311.7M
Stockholders' Equity
AWRE
AWRE
ROIV
ROIV
Q1 26
Q4 25
$26.1M
$4.3B
Q3 25
$27.2M
$4.4B
Q2 25
$28.1M
$4.3B
Q1 25
$29.5M
$4.7B
Q4 24
$30.9M
$5.2B
Q3 24
$31.9M
$5.2B
Q2 24
$32.6M
$5.4B
Total Assets
AWRE
AWRE
ROIV
ROIV
Q1 26
$33.2M
Q4 25
$37.2M
$5.2B
Q3 25
$40.3M
$5.1B
Q2 25
$38.1M
$5.0B
Q1 25
$39.9M
$5.4B
Q4 24
$42.6M
$5.8B
Q3 24
$43.7M
$6.2B
Q2 24
$43.2M
$6.5B
Debt / Equity
AWRE
AWRE
ROIV
ROIV
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AWRE
AWRE
ROIV
ROIV
Operating Cash FlowLast quarter
$-196.5M
Free Cash FlowOCF − Capex
$-201.4M
FCF MarginFCF / Revenue
-10076.0%
Capex IntensityCapex / Revenue
246.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-776.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AWRE
AWRE
ROIV
ROIV
Q1 26
Q4 25
$1.0M
$-196.5M
Q3 25
$-2.4M
$-185.7M
Q2 25
$-1.2M
$-204.4M
Q1 25
$-2.9M
$-172.6M
Q4 24
$683.0K
$-207.3M
Q3 24
$-765.0K
$-266.8M
Q2 24
$-668.0K
$-192.8M
Free Cash Flow
AWRE
AWRE
ROIV
ROIV
Q1 26
Q4 25
$926.0K
$-201.4M
Q3 25
$-193.5M
Q2 25
$-208.4M
Q1 25
$-3.0M
$-173.4M
Q4 24
$-209.1M
Q3 24
$-267.8M
Q2 24
$-193.8M
FCF Margin
AWRE
AWRE
ROIV
ROIV
Q1 26
Q4 25
19.9%
-10076.0%
Q3 25
-12317.8%
Q2 25
-9604.5%
Q1 25
-82.7%
438.1%
Q4 24
-2318.5%
Q3 24
-5984.4%
Q2 24
-2425.5%
Capex Intensity
AWRE
AWRE
ROIV
ROIV
Q1 26
Q4 25
2.6%
246.9%
Q3 25
0.0%
499.6%
Q2 25
0.0%
185.9%
Q1 25
1.2%
-2.0%
Q4 24
20.3%
Q3 24
0.0%
22.3%
Q2 24
12.1%
Cash Conversion
AWRE
AWRE
ROIV
ROIV
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-1.22×
Q3 24
Q2 24
-2.02×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons